Objective Balloon-occluded retrograde transvenous obliteration (B-RTO) has recently been introduced as a new interventional modality to prevent fatal bleeding from solitary gastric varices. A large portal-systemic shunt including gastric varices also causes severe encephalopathy in somecirrhotic patients. In this study, we evaluated the effect of B-RTOas a candidate therapeutic methodto treat chronic recurrent hepatic encephalopathy due mainly to a portal-systemic shunt.
Introduction
It is well knownthat patients with liver cirrhosis experience manycomplications including variceral bleeding, hepatic encephalopathy, ascites, jaundice, and renal dysfunction (1) . As variceral bleeding is fatal, many therapies have been developed such as endoscopic sclerotherapy (EIS) with 5%ethano-lamine oleate or endoscopic variceral ligation therapy (EVL) (2, 3) . Although EIS and EVL are very effective and have de- creased the death rate of the patients with esophageal varices (2, 3) , such therapies have limitations in the use for treatment of cardiac varices. Instead of endoscopic modalities, interventional radiology represented by balloon-occluded retrograde transvenous oblitation (B-RTO) has recently been described as a new therapy for solitary gastric varices (4) . On the other hand, encephalopathy in cirrhotic patients is not easily treatable. There are two types of encephalopathies in liver cirrhosis; portal-systemic encephalopathy and end-stage hepatic encephalopathy in severe liver dysfunction ( 1) . Portalsystemic encephalopathy is muchdifferent from the latter encephalopathy in the pathogenesis. The portal-systemic shunt involves a blood flow from mainly the supramesenteric vein to the systemic vein, and provides high systemic blood ammonia levels. Solitary gastric varices are constructed with spleno-renal shunt, and have also been reported to cause severe encephalopathy in some patients. It has been preliminarily reported that patients whohad underwent B-RTOfor cardiac varices were sometimes free of encephalopathy thereafter. Such cases suggest that B-RTOoccluded the portal-systemic shunt, which might have been a cause of varices as well as encephalopathy. In light of this, a hypothesis can be further expanded that BRTOis a candidate treatment for a chronic portal-systemic encephalopathy in cirrhotic patients regardless of the presence of cardiac varices. To test this hypothesis, we evaluated the effect of B-RTOon chronic recurrent hepatic encephalopathy in cirrhotic patients 
Patients and Methods
Since July 1995, we have treated 43 cirrhotic patients with chronic recurrent hepatic encephalopathy. Amongthem, six patients (three males and three females) were enrolled in this study after fulfilling the inclusion criteria of both the resistance to conventional treatment of hepatic encephalopathy and the presence of angiographically proven portal-systemic shunt. Their age, sex, serum hepatitis virus markers, and modified Child's classification are given in Table 1 . They had been admitted to our hospital at least 3 times or more due to chronic recurrent encephalopathy of grade III, and were treated at each episode with drip infusion of branched-chain amino acid enriched solution. They had been also treated with oral lactulose throughout both the in-and outpatient period. Wethen checked for the existence of portal-systemic shunts using magnetic resonance angiography (MRA)and dynamic X-ray computed tomography (CT), and identified a variety of portal-systemic shunts in all patients ( Table 1 ). The diameter of the shunts ranged from 1.0 cm to 2.0 cm. Gastro-esophageal varices was found in only one patient (Patient No. 6). B-RTOwas carried out only once in patients No. 1-5 according to the method of Kanagawa et al (4) using 5%ethano-lamine oleate with iopamidole (5%EO)to obliterate the portal-systemic shunt for 30 minutes. Patient No. 6 received BRTOthree times to simultaneously treat her solitary gastric varices. The volume of infused 5%EOranged from 10 to 14 ml (Table 1) . Median observation period after B-RTOwas 29 months (range 23-46 months) ( Table 1) . During this period, we monitored the patients by physical examination and blood biochemistry analysis basically every 2 weeks, and with MRA and dynamic CT every 3 months. This study was approved by each institution's review board for humanresearch. Written informed consent was obtained from each patient or his/her relatives in advance of B-RTO.
Results
Complete obliteration was achieved without major complications such as development/enlargement of esophago-cardiac varices or increase in ascites. Varices of Patient No. 6 disappeared. Encephalopathic symptoms had disappeared clinically in all 6 patients within 2 days after B-RTO. Thereafter, they continued to receive samemedical treatments other than branched-chain amino acid enriched solution. They were free of encephalopathy during the following 6 months (Fig. 1) . 
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Blood ammonia levels were significantly decreased one month after B-RTOas compared with those before B-RTO, and remained low up to 12 months (Fig. 2) . B-RTO did not affect serum aspartate aminotransferase activity, total bilirubin and albumin concentrations (Fig. 2) , or plasma prothrombin time.
Discussion
Chronic recurrent hepatic encephalopathy is often associated with portal-systemic shunt in cirrhosis patients (5). We usually treat hepatic encephalopathy of this type with lactulose and oral branched-chain amino acid supplementation (6) . In general, these therapies are effective to improve each episode and to prevent recurrence of hepatic encephalopathy. However, wesometimesexperience a limitation in therapeutic as well as preventive effects of these modalities in a population of patients with portal-systemic shunt, and in such particular patients, repeat encephalopathic episode occurs quite frequently. Although the incidence of these resistant cases has not ever been described, the present study provides an estimation that they account for approximately 14% (6/43) of chronic recurrent hepatic encephalopathy.
On the other hand, many cirrhotic patients have esophago-B -RTOfor Portal-systemic Encephalopathy cardiac varices. Whenvariceral bleeding impends, these patients undergo endoscopic therapies such as sclerotherapy (3) or ligation (2) . However, it is difficult to treat solitary gastric varices with EVLor EIS. To overcome such limitations of endoscopic modalities, interventional radiology including balloonoccluded retrograde transvenous obliteration (B-RTO) has been recently introduced for clinical use to treat solitary gastric varices (4). In addition to excellent hemostatic effects of B-RTO (4), it has also been reported that a patient, who had received B-RTOfor varices, was free of encephalopathy for a short period following the procedure (7). The effectiveness of B-RTO depends basically on its ability to obstruct portal-systemic shunt. Therefore, it can be hypothesized that B-RTOwill be a possible new therapy for portal-systemic encephalopathy even in patients without cardiac varices. Wedemonstrated this hypothesis in 6 patients by significantly reducing the blood ammonia level and eradicating encephalopathy. Possible adverse effects such as esophago-gastric varices and ascites were not induced by B-RTO. Another merit of B-RTOwas that the method did not affect the functional reserve of the liver. Although several other methods are available to obstruct portal-systemic shunt including surgical ligation, a surgical approach may cause too great of a load on severe cirrhosis. Transjuglar intrahepatic portal-systemic shunt (TIPS) is one of the moreuseful therapies for the prevention of recurrent variceral bleeding, and has also been reported as a useful therapy for chronic hepatic encephalopathy (8) . TIPS has another benefit to avoid the risk of developing refractory ascites due to shunt occlusion. However, TIPS seems hardly applicable to severe atrophic cirrhosis caused by viral hepatitis. Hence, when patients experience liver atrophy and spleno-renal shunt, BRTOis a safer and less invasive method, and TIPS should be selected as a second choice to treat hepatic encephalopathy in particularly. Transjugular obliteration (TJO), a method similar to B-RTO,has been reported as an effective approach to portal-systemic shunts as well (9), but requires great skill. Wetreated cirrhosis patients who experienced portal-systemic encephalopathywithout esophagocardiacvarices only once by B-RTOat first, while several sessions of B-RTOare usually required to obliterate varices as in Patient No. 6. Single session B-RTOseems sufficient to prevent recurrent encephalopathy up to 18 months (median), but might be feasible for recirculation of the shunt. Another benefit of the single session B-RTOis the lack of complications such as ascites, which are often observed after multiple sessions of B-RTO(4). As to the duration of the effect on hepatic encephalopathy, other interventional radiological therapies for shunt occlusion are limited to within one year (7, 8) . However we cannot assert that the single B-RTOis more beneficial than multiple administrations for hepatic encephalopathy in terms of the effective period and the incidence of adverse effects. Wesuggest the necessity of further study to clarify this concern. As to the machanismof the effect of B-RTOon portal-systemic encephalopathy, single session B-RTOas described in this study might have decreased the shunt flow and recovered the hepatic blood flow. It is considered that the decrease of blood ammonia level was brought about by the recovered hepatic blood flow and by the enhanced ammoniadetoxication by the liver. The Child' s classification in two-thirds of our cases was B, which suggests another condition for recovery from hepatic encephalopathy with single session B-RTO,i.e. the functional reserve of the cirrhotic liver is better conserved to process the increased ammonia load.
In conclusion, B-RTOis an effective treatment for chronic recurrent portal-systemic encephalopathy. Candidates for BRTOshould be defined more precisely by a future prospective study.
